Kairos Pharma, LTD. (KAPA) — SEC Filings

Overview

Kairos Pharma, LTD. (KAPA) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 14, 2025: Kairos Pharma, LTD. (KAPA) reported a net loss of $4.082 million for the nine months ended September 30, 2025, a significant increase from the $1.623 million net loss in the same period of 2024. The company generated no revenue in either period. Operating expenses surged, with research and developme

Sentiment Summary

Across 39 filings, the sentiment breakdown is: 2 bearish, 36 neutral, 1 mixed. The dominant filing sentiment for Kairos Pharma, LTD. is neutral.

Filing Type Overview

Kairos Pharma, LTD. (KAPA) has filed 4 10-Q, 22 8-K, 2 10-K/A, 1 DEF 14A, 2 S-1, 1 10-K, 7 S-1/A with the SEC between Feb 2024 to Nov 2025.

Filings by Year

2025 · 2024

Recent Filings (39)

• Kairos Pharma's Net Loss Widens to $4.08M Amid Soaring R&D Costs — 10-Q · Nov 14, 2025 Risk: high
  Kairos Pharma, LTD. (KAPA) reported a net loss of $4.082 million for the nine months ended September 30, 2025, a significant increase from the $1.623 million ne
• Kairos Pharma Announces Board & Executive Changes — 8-K · Oct 15, 2025 Risk: medium
  Kairos Pharma, LTD. announced on October 8, 2025, a change in its board of directors and executive compensation arrangements. The filing details the departure o
• Kairos Pharma Enters Material Definitive Agreement — 8-K · Oct 7, 2025 Risk: medium
  On October 1, 2025, Kairos Pharma, Ltd. entered into a material definitive agreement. The company, incorporated in Delaware with its principal executive offices
• Kairos Pharma Files 8-K Report — 8-K · Sep 18, 2025 Risk: low
  On September 18, 2025, Kairos Pharma, Ltd. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits." No specifi
• Kairos Pharma Files 8-K — 8-K · Sep 11, 2025 Risk: low
  On September 11, 2025, Kairos Pharma, Ltd. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits." No specifi
• Kairos Pharma Files 8-K — 8-K · Sep 3, 2025 Risk: low
  Kairos Pharma, Ltd. filed an 8-K on September 3, 2025, reporting "Other Events" and "Financial Statements and Exhibits." The filing does not disclose specific m
• Kairos Pharma's Losses Mount Amid R&D Surge, Secures Fresh Capital — 10-Q · Aug 12, 2025 Risk: high
  Kairos Pharma, LTD. (KAPA) reported a significant increase in net loss for the six months ended June 30, 2025, reaching $2,684,000, a substantial rise from the
• Kairos Pharma Files 10-K/A Amendment for FY24 Report — 10-K/A · Jul 28, 2025 Risk: medium
  Kairos Pharma, LTD. (KAPA) filed a 10-K/A Amendment No. 2 for the fiscal year ended December 31, 2024, indicating corrections or updates to its previously filed
• Kairos Pharma Files 8-K: Other Events & Financials — 8-K · Jul 15, 2025 Risk: medium
  Kairos Pharma, Ltd. filed an 8-K on July 15, 2025, reporting "Other Events" and "Financial Statements and Exhibits." The filing does not contain specific detail
• Kairos Pharma Files 8-K: Material Agreement & Shareholder Vote — 8-K · Jun 12, 2025 Risk: medium
  On June 10, 2025, Kairos Pharma, Ltd. filed an 8-K report detailing a material definitive agreement, the submission of matters to a vote of security holders, an
• Kairos Pharma Files 8-K — 8-K · Jun 3, 2025 Risk: low
  On June 3, 2025, Kairos Pharma, Ltd. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," with no specific
• Kairos Pharma Files Q1 2025 10-Q — 10-Q · May 14, 2025 Risk: low
  Kairos Pharma, LTD. filed its 10-Q for the period ending March 31, 2025. The company, located in Los Angeles, CA, operates in the Pharmaceutical Preparations se
• Kairos Pharma Files 2025 Proxy Statement — DEF 14A · May 1, 2025 Risk: low
  Kairos Pharma, LTD. filed its definitive proxy statement (DEF 14A) on May 1, 2025, for the fiscal year ending December 31, 2024. The company, incorporated in De
• Kairos Pharma Files 2024 Annual Report Amendment — 10-K/A · Apr 29, 2025 Risk: low
  Kairos Pharma, LTD. filed an amendment (10-K/A) to its annual report for the fiscal year ending December 31, 2024. The company, incorporated in Delaware with it
• Kairos Pharma Appoints Marcum LLP as New Auditor — 8-K · Apr 28, 2025 Risk: low
  Kairos Pharma, Ltd. announced on April 23, 2025, a change in its certifying accountant. The company has dismissed its previous independent registered public acc
• Kairos Pharma Files 8-K — 8-K · Apr 24, 2025 Risk: low
  On April 24, 2025, Kairos Pharma, Ltd. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," with no specif
• Kairos Pharma Files for Public Offering — S-1 · Apr 22, 2025 Risk: medium
  Kairos Pharma, Ltd. filed an S-1 registration statement on April 21, 2025, to offer its securities to the public. The company, incorporated in Delaware with its
• Kairos Pharma Files 2024 10-K — 10-K · Apr 15, 2025 Risk: low
  Kairos Pharma, LTD. filed its 2024 10-K on April 15, 2025, reporting its financial performance for the fiscal year ending December 31, 2024. The company, operat
• Kairos Pharma Files 8-K: Other Events & Exhibits — 8-K · Mar 20, 2025 Risk: low
  On March 20, 2025, Kairos Pharma, Ltd. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," with no specif
• Kairos Pharma Files 8-K Report — 8-K · Feb 26, 2025 Risk: low
  On February 26, 2025, Kairos Pharma, LTD. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits" without deta
• Kairos Pharma Files 8-K: Other Events & Financials — 8-K · Feb 6, 2025 Risk: low
  On February 6, 2025, Kairos Pharma, LTD. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indicating u
• Kairos Pharma Files for IPO — S-1 · Jan 29, 2025 Risk: medium
  Kairos Pharma, LTD. filed an S-1 form on January 29, 2025, indicating plans for an initial public offering. The company, based in Los Angeles, CA, operates in t
• Kairos Pharma Enters Material Agreement, Reports Equity Sales — 8-K · Jan 17, 2025 Risk: medium
  On January 16, 2025, Kairos Pharma, Ltd. entered into a material definitive agreement. The company also reported on unregistered sales of equity securities and
• Kairos Pharma Files 8-K on Agreements and Equity Sales — 8-K · Jan 14, 2025 Risk: medium
  On January 14, 2025, Kairos Pharma, Ltd. filed an 8-K report detailing a material definitive agreement, unregistered sales of equity securities, and financial s
• Kairos Pharma Files 8-K on Leadership Changes & Financials — 8-K · Dec 13, 2024 Risk: medium
  Kairos Pharma, LTD. filed an 8-K on December 13, 2024, reporting on the departure of directors, election of new directors, appointment of officers, and compensa
• Kairos Pharma Files 8-K — 8-K · Nov 19, 2024 Risk: low
  Kairos Pharma, LTD. filed an 8-K on November 19, 2024, to report on a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contai
• Kairos Pharma Files Q3 2024 10-Q — 10-Q · Nov 14, 2024 Risk: medium
  Kairos Pharma, LTD. filed its 10-Q for the period ending September 30, 2024. The company, incorporated in Delaware and operating in the pharmaceutical preparati
• Kairos Pharma Files 8-K Report — 8-K · Oct 10, 2024 Risk: low
  On October 9, 2024, Kairos Pharma, Ltd. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits." No specific f
• Kairos Pharma Enters Material Definitive Agreement — 8-K · Oct 4, 2024 Risk: medium
  On October 1, 2024, Kairos Pharma, Ltd. entered into a material definitive agreement. The company, incorporated in Delaware with its principal executive offices
• Kairos Pharma Enters Material Definitive Agreement — 8-K · Sep 27, 2024 Risk: medium
  On September 23, 2024, Kairos Pharma, Ltd. entered into a material definitive agreement. The company, incorporated in Delaware with its principal executive offi
• Kairos Pharma Enters Material Definitive Agreement — 8-K · Sep 24, 2024 Risk: medium
  On September 20, 2024, Kairos Pharma, LTD. entered into a material definitive agreement. The company, incorporated in Delaware with its principal executive offi
• Kairos Pharma Enters Material Definitive Agreement — 8-K · Sep 17, 2024 Risk: medium
  On September 16, 2024, Kairos Pharma, Ltd. entered into a material definitive agreement. The filing does not provide specific details about the agreement, its c
• Kairos Pharma Files S-1/A Amendment for IPO — S-1/A · Aug 16, 2024 Risk: medium
  Kairos Pharma, Ltd. filed an S-1/A amendment on August 16, 2024, for its initial public offering under registration number 333-274805. The company, incorporated
• Kairos Pharma Files S-1/A Amendment for IPO — S-1/A · Jun 4, 2024 Risk: medium
  Kairos Pharma, Ltd. filed an S-1/A amendment on June 3, 2024, for its initial public offering under registration number 333-274805. The company, incorporated in
• Kairos Pharma Files S-1/A Amendment for IPO — S-1/A · May 24, 2024 Risk: medium
  Kairos Pharma, Ltd. filed an S-1/A amendment on May 24, 2024, for its initial public offering under registration number 333-274805. The company, incorporated in
• Kairos Pharma Files S-1/A Amendment for IPO — S-1/A · May 20, 2024 Risk: medium
  Kairos Pharma, Ltd. filed an S-1/A amendment on May 20, 2024, for its initial public offering. The company, incorporated in Delaware, is seeking to register an
• Kairos Pharma, Ltd. Files Amendment 4 to S-1 Registration Statement — S-1/A · May 13, 2024 Risk: low
  Kairos Pharma, LTD. (KAPA) filed a Amended IPO Registration (S-1/A) with the SEC on May 13, 2024. Kairos Pharma, Ltd. filed Amendment No. 4 to its Form S-1 Regi
• Kairos Pharma, LTD. Files Amendment to S-1 Registration Statement — S-1/A · May 1, 2024 Risk: low
  Kairos Pharma, LTD. (KAPA) filed a Amended IPO Registration (S-1/A) with the SEC on May 1, 2024. Kairos Pharma, LTD. filed an S-1/A (Amendment No. 3) with the S
• Kairos Pharma, Ltd. Files Amendment 2 to S-1 Registration Statement — S-1/A · Feb 14, 2024 Risk: low
  Kairos Pharma, LTD. (KAPA) filed a Amended IPO Registration (S-1/A) with the SEC on February 14, 2024. Kairos Pharma, Ltd. filed an S-1/A on February 14, 2024.

Risk Profile

Risk Assessment: Of KAPA's 39 recent filings, 2 were flagged as high-risk, 19 as medium-risk, and 18 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Financial Highlights

Key financial metrics from Kairos Pharma, LTD.'s most recent 10-Q filing (Nov 14, 2025):

• Revenue: $0
• Net Income: -$4.082M
• EPS: N/A
• Debt-to-Equity: N/A
• Cash Position: $5.575M
• Operating Margin: N/A
• Total Assets: N/A
• Total Debt: N/A

Key Executives

• John S. Yu, M.D.
• Megan J. Penick, Esq.
• Spencer G. Feldman, Esq.
• Dakota J. Forsyth, Esq.

Industry Context

Kairos Pharma operates in the highly competitive and capital-intensive early-stage biotechnology sector, specifically focusing on immunotherapy and cell therapy for oncology. This field is characterized by long development cycles, significant R&D investment, and stringent regulatory pathways. Success hinges on groundbreaking scientific innovation, successful clinical trials, and securing substantial funding to navigate these challenges.

Top Tags

sec-filing (7) · 8-K (6) · financials (6) · material-agreement (6) · pharmaceutical (6) · ipo (6) · 8-k (5) · regulatory-filing (5) · filing (4) · SEC Filing (4)

Key Numbers

• Net Loss: $4.082M — Increased from $1.623M in 2024 for the nine months ended September 30, 2025
• Revenues: $0 — No revenue generated for the nine months ended September 30, 2025 and 2024
• Research and Development Expenses: $1.597M — Increased from $242K in 2024 for the nine months ended September 30, 2025
• General and Administrative Expenses: $2.560M — Increased from $655K in 2024 for the nine months ended September 30, 2025
• Cash and Cash Equivalents: $5.575M — Increased from $1.272M at December 31, 2024
• Total Shareholders' Equity: $7.664M — Increased from $4.776M at December 31, 2024
• Common Shares Outstanding: 20,821,353 — As of November 14, 2025, up from 13,736,597 at December 31, 2024
• Net Cash Used in Operating Activities: $2.357M — For the nine months ended September 30, 2025
• Net Cash Provided by Financing Activities: $6.660M — For the nine months ended September 30, 2025
• Deferred Offering Costs: $1,308 — Related to the ELOC as of September 30, 2025
• SEC File Number: 001-42275 — Identifies the company's filing with the SEC.
• IRS Employer Identification No.: 46-2993314 — Company's tax identification number.
• Proceeds from Warrants: $3.06M — Key financing source for the six months ended June 30, 2025.
• Subsequent ELOC Proceeds: $3.69M — Additional capital secured after quarter-end, extending liquidity runway.
• Accumulated Deficit: $11.50M — Grew from $8.82M, reflecting continued losses since inception.

Frequently Asked Questions